Vireo Growth (VREOF)
OTHER OTC:VREOF
VREOF Stock Chart & Stats
$0.41
$0.02(3.15%)
At close: 4:00 PM EST
$0.41
$0.02(3.15%)
Day’s Range― - ―
52-Week Range$0.32 - $0.80
Previous CloseN/A
Volume345.43K
Average Volume (3M)192.61K
Market Cap
$507.36M
Enterprise Value$404.70M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.12
Next Earnings
Aug 06, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,147,581,400
10 Day Avg. Volume100,700
30 Day Avg. Volume192,613
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)0.03
Revenue Forecast (FY)$477.49M
Vireo Growth News
VREOF FAQ
What was Vireo Growth’s price range in the past 12 months?
Vireo Growth lowest stock price was $0.32 and its highest was $0.80 in the past 12 months.
What is Vireo Growth’s market cap?
Vireo Growth’s market cap is $507.36M.
When is Vireo Growth’s upcoming earnings report date?
Vireo Growth’s upcoming earnings report date is Aug 06, 2026 which is in 64 days.
How were Vireo Growth’s earnings last quarter?
Vireo Growth released its earnings results on May 12, 2026. The company reported -$0.013 earnings per share for the quarter, missing the consensus estimate of $0.005 by -$0.018.
Is Vireo Growth overvalued?
According to Wall Street analysts Vireo Growth’s price is currently Overvalued.
Does Vireo Growth pay dividends?
Vireo Growth does not currently pay dividends.
What is Vireo Growth’s EPS estimate?
Vireo Growth’s EPS estimate is 0.02.
How many shares outstanding does Vireo Growth have?
Vireo Growth has 1,147,581,400 shares outstanding.
What happened to Vireo Growth’s price movement after its last earnings report?
Vireo Growth reported an EPS of -$0.013 in its last earnings report, missing expectations of $0.005. Following the earnings report the stock price went up 0.75%.
Which hedge fund is a major shareholder of Vireo Growth?
Currently, no hedge funds are holding shares in VREOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vireo Growth Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.17%
12-Months-Change
Fundamentals
Return on Equity
-47.54%
Trailing 12-Months
Asset Growth
235.25%
Trailing 12-Months
Company Description
Vireo Growth
Vireo Health International, Inc. is a holding company, which engages in the cultivation, production, and sale of medical cannabis. Its products include medical marijuana extracts in the form of oils, vaporizers, and capsules. The company was founded on November 23, 2004 and is headquartered in Minneapolis, MN.
VREOF Company Deck
VREOF Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized transformative M&A that materially increased reported revenue and scale (GAAP revenue +333% YoY; pro forma revenue $210.2M), improved profitability (adjusted EBITDA growth and margin expansion), and a strong cash position (~$137.8M). Strategic partnerships (Glass House, FLUENT) and leadership positions in key states were highlighted as durable positives. Key risks discussed include integration execution across many acquisitions (Florida as a major near-term test), modest organic pro forma growth (+5% YoY), GAAP non-cash adjustments affecting comparability, localized operational volatility (Minnesota), regulatory/CapEx restraint evidenced by the Texas license sale, and a high share count. On balance, the financial improvements, scale and cash position outweigh the integration and regulatory risks presented on the call.View all VREOF earnings summariesTechnical Analysis
NeutriSci International
―
ZYUS Life Sciences
―
Luff Enterprises
―
―
Hash Corporation
―
Ownership Overview
12.32% Insiders
<0.01% Other Institutional Investors
87.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---